AAAAAA

   
Results: 1-16 |
Results: 16
Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer
Authors: Birner, P Oberhuber, G Stani, J Reithofer, C Samonigg, H Hausmaninger, H Kubista, E Kwasny, W Kandioler-Eckersberger, D Gnant, M Jakesz, R
Citation: P. Birner et al., Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer, CLIN CANC R, 7(6), 2001, pp. 1669-1675
Prognostic relevance of three histological grading methods in breast cancer
Authors: Latinovic, L Heinze, G Birner, P Samonigg, H Hausmaninger, H Kubista, E Kwasny, W Gnant, M Jakesz, R Oberhuber, G
Citation: L. Latinovic et al., Prognostic relevance of three histological grading methods in breast cancer, INT J ONCOL, 19(6), 2001, pp. 1271-1277
Heat treatment of hepatocellular carcinoma cells: Increased levels of heatshock proteins 70 and 90 correlate with cellular necrosis
Authors: Schueller, G Paolini, P Friedl, J Stift, A Dubsky, P Bachleitner-Hofmann, T Jakesz, R Gnant, M
Citation: G. Schueller et al., Heat treatment of hepatocellular carcinoma cells: Increased levels of heatshock proteins 70 and 90 correlate with cellular necrosis, ANTICANC R, 21(1A), 2001, pp. 295-300
Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer
Authors: Janschek, E Kandioler-Eckersberger, D Ludwig, C Kappel, S Wolf, B Taucher, S Rudas, M Gnant, M Jakesz, R
Citation: E. Janschek et al., Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer, BREAST CANC, 67(1), 2001, pp. 1-8
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients
Authors: Kandioler-Eckersberger, D Ludwig, C Rudas, M Kappel, S Janschek, E Wenzel, C Schlagbauer-Wadl, H Mittlbock, M Gnant, M Steger, G Jakesz, R
Citation: D. Kandioler-eckersberger et al., TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients, CLIN CANC R, 6(1), 2000, pp. 50-56
Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of athymidine kinase-deleted mutant
Authors: Puhlmann, M Brown, CK Gnant, M Huang, J Libutti, SK Alexander, HR Bartlett, DL
Citation: M. Puhlmann et al., Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of athymidine kinase-deleted mutant, CANC GENE T, 7(1), 2000, pp. 66-73
Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast
Authors: Gebhard, B Gnant, M Schutz, G Roka, S Weigel, G Kandioler, D Taucher, S Grunberger, T Roth, E Jakesz, R Spittler, A
Citation: B. Gebhard et al., Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breast, ANTICANC R, 20(6B), 2000, pp. 4599-4604
Surgical axillary lymph node dissection. Still standard procedure or obsolete method?
Authors: Bachleitner-Hofmann, T Gnant, M
Citation: T. Bachleitner-hofmann et M. Gnant, Surgical axillary lymph node dissection. Still standard procedure or obsolete method?, ZBL CHIR, 125(10), 2000, pp. 822-829
Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy
Authors: Puhlmann, M Gnant, M Brown, CK Alexander, HR Bartlett, DL
Citation: M. Puhlmann et al., Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy, HUM GENE TH, 10(4), 1999, pp. 649-657
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients
Authors: Kucera, E Speiser, P Gnant, M Szabo, L Samonigg, H Hausmaninger, H Mittlbock, M Fridrik, M Seifert, M Kubista, E Reiner, A Zeillinger, R Jakesz, R
Citation: E. Kucera et al., Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients, EUR J CANC, 35(3), 1999, pp. 398-405
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
Authors: Jakesz, R Hausmaninger, H Haider, K Kubista, E Samonigg, H Gnant, M Manfreda, D Tschurtschenthaler, G Kolb, R Stierer, M Fridrik, M Mlineritsch, B Steindorfer, P Mittlbock, M Steger, G
Citation: R. Jakesz et al., Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer, J CL ONCOL, 17(6), 1999, pp. 1701-1709
MHC-class-I expression in human breast cancer correlates with nuclear localization of the 90 kDa heat-shock-protein
Authors: Gebhard, B Schutz, G Ecker, RC Steiner, GE Rudas, M Gnant, M Oehler, R
Citation: B. Gebhard et al., MHC-class-I expression in human breast cancer correlates with nuclear localization of the 90 kDa heat-shock-protein, ANTICANC R, 19(6B), 1999, pp. 5293-5297
Clinical phase II evaluation of the combination therapy with Docetaxel andEpidoxorubicin in the neoadjuvant, cytostatic treatment on patients with primary breast cancer (T1-4, N0-2, M0)
Authors: Wenzel, C Schmidinger, M Locker, GJ Taucher, S Gnant, M Jakesz, R Steger, GG
Citation: C. Wenzel et al., Clinical phase II evaluation of the combination therapy with Docetaxel andEpidoxorubicin in the neoadjuvant, cytostatic treatment on patients with primary breast cancer (T1-4, N0-2, M0), WIEN KLIN W, 111(20), 1999, pp. 843-850
Indications and contraindications for breast preservation in patients withbreast cancer
Authors: Jakesz, R Gebhard, B Gnant, M Taucher, S
Citation: R. Jakesz et al., Indications and contraindications for breast preservation in patients withbreast cancer, CHIRURG, 70(4), 1999, pp. 394-399
In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha, is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII)
Authors: Wu, PC Alexander, HR Huang, J Hwu, P Gnant, M Berger, AC Turner, E Wilson, O Libutti, SK
Citation: Pc. Wu et al., In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha, is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII), CANCER RES, 59(1), 1999, pp. 205-212
Neoadjuvant chemotherapy in patients with breast cancer
Authors: Jakesz, R Taucher, S Gnant, M Gebhard, B Kandioler, D Rudas, M Djavanmard, M Steger, G
Citation: R. Jakesz et al., Neoadjuvant chemotherapy in patients with breast cancer, ZBL CHIR, 123, 1998, pp. 147-150
Risultati: 1-16 |